Navigation Links
Drugs Previously Thought to Be Toxic May Stop Spread of Cancer
Date:3/30/2012

FRIDAY, March 30 (HealthDay News) -- Two drugs previously thought to be too toxic for human cancer treatment may stop the growth of cancer cells without killing healthy cells and damaging DNA when used in small doses, researchers have found.

Unlike conventional chemotherapy drugs, which poison and kill any rapidly dividing cells by damaging cellular machinery and DNA, these drugs -- azacitidine (AZA) and decitabine (DAC) -- specifically target cancer stem cells, which cause cancer to spread and are resistant to most drugs.

"Low doses of AZA and DAC may reactivate genes that stop cancer growth without causing immediate cell killing or DNA damage," Dr. Stephen Baylin, a professor of oncology and deputy director of the Johns Hopkins Kimmel Cancer Center in Baltimore, said in a news release from Hopkins.

Although AZA and DAC were dismissed as too toxic for the treatment of common cancers, the drugs have been effective in treating a small number of patients with advanced lung cancer and myelodysplastic syndrome. Based on those positive clinical outcomes, the Johns Hopkins researchers decided to re-evaluate the drugs for use in cancer treatment.

Back in the lab, they treated leukemia, breast cancer, lung cancer and colon cancer cell lines with low doses of AZA and DAC for three days. A week later, the treated cells were transplanted into mice and observed for up to 20 weeks.

The researchers found the anticancer effects of the drugs continued long after treatment stopped.

After treatment with AZA and DAC, the cancer cells returned to a more normal state and eventually died, Baylin said.

"Our findings match evidence from recent clinical trials suggesting that the drugs shrink tumors more slowly over time as they repair altered mechanisms in cells and genes return to normal function," Baylin said.

The team noted, however, that more research is needed to determine exactly how the drugs work.

Clinical trials already have begun among patients in advanced stages of breast and lung cancer, the researchers said, and trials in colon cancer patients also are planned.

The researchers noted previous research has shown the drugs could make other anticancer treatments more effective. The drugs could become part of a combined treatment approach for certain cancers, they said.

The findings, which were published recently in the journal Cancer Cell, are expected to be presented Sunday at a Stand Up to Cancer press event in Chicago.

More information

The U.S. National Cancer Institute provides more information on cancer stem cells.

-- Mary Elizabeth Dallas

SOURCE: The American Association for Cancer Research, news release, March 27, 2012.


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Caring Teachers May Help Keep Kids From Trying Alcohol, Drugs
2. Unprecedented academic-industry collaboration seeks new drugs and novel treatments for autism
3. Closing hole in the heart no better than drugs in preventing strokes
4. Study finds intrauterine exposure to drugs does not affect academic achievement test scores
5. Solving mystery of how sulfa drugs kill bacteria yields 21st century drug development target
6. Efforts to Improve Research on Kids Drugs Paying Off: Report
7. FDA Moves to Head Off Shortages of 2 Cancer Drugs
8. Alzheimers drugs may have adverse side effects
9. Certain Cancer Drugs May Have Fatal Side Effects: Analysis
10. Drugs targeting chromosomal instability may fight a particular breast cancer subtype
11. Websites advertising cholesterol-lowering drugs of poor quality
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drugs Previously Thought to Be Toxic May Stop Spread of Cancer
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical companies are held ... with process innovation in drug formulation and manufacturing. CoreRx offers its clients ... equipment in support of their development and manufacturing goals. , The company ...
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers ... back pain with a reputable physician in their area, announces the launch of a ... information for patients who are looking for reputable physicians to help them with back ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest ... chronic problems, I focus on preventative care with all my patients to alleviate possible future ... always feel free to contact my office and my trained staff will assist you in ...
(Date:4/25/2017)... ... April 25, 2017 , ... Emergency Physician and Distinguished Professor of Emergency ... Series, Outliers in Writing, set to publish in summer 2017. , Dr. Bobrow, ... University of Arizona College of Medicine. He also serves as Medical Director for the ...
(Date:4/25/2017)... ... ... Vetoquinol USA® , a world-class developer of veterinarian-approved ... EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin UCII ... The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and joints. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Company,s consumer product development program, based on its ... for Investigative Dermatology (SID) 76 th Annual ... promote the sciences relevant to skin health and ...
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
Breaking Medicine Technology: